iHuman (IH) director Chi Hanfeng reports options on 54,000 Class A shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
iHuman Inc. director Chi Hanfeng has filed an initial ownership report showing holdings of stock options linked to the company’s Class A ordinary shares. The filing lists options covering 27,000 underlying shares at an exercise price of $0.0500 per share, expiring on November 30, 2030, and another block covering 27,000 underlying shares at the same exercise price, expiring on December 15, 2032.
According to the footnotes, the 2030 options were granted on November 30, 2020 and vested over three years, while the 2032 options were granted on December 15, 2022 and vest in equal annual installments over four years. All holdings are reported as directly owned.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Chi Hanfeng
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
Holdings After Transaction:
Options — 27,000 shares (Direct)
Footnotes (1)
- These options were granted on November 30, 2020 and vested over a three-year period, with 33.33% of the options vesting on October 8, 2021, 33.33% on October 8, 2022, and the remaining 33.34% on October 8, 2023. These options were granted on December 15, 2022 and vest in equal installments over a four-year period, with 25% of the options vest on each anniversary after the grant date.
FAQ
What does the iHuman (IH) Form 3 filing by Chi Hanfeng report?
The Form 3 reports that director Chi Hanfeng holds stock options over iHuman Class A ordinary shares. It details two option grants, their exercise price of $0.0500 per share, vesting schedules, and expirations in 2030 and 2032, all shown as directly owned.
What are the exercise prices and expiration dates of Chi Hanfeng’s iHuman options?
Both option grants carry an exercise price of $0.0500 per share. One grant, over 27,000 underlying shares, expires on November 30, 2030, while the second, also for 27,000 underlying shares, expires on December 15, 2032, according to the filing.
How do Chi Hanfeng’s iHuman option grants vest according to the Form 3 footnotes?
The November 30, 2020 grant vested over three years, with 33.33% vesting on each of October 8, 2021 and October 8, 2022, and 33.34% on October 8, 2023. The December 15, 2022 grant vests in four equal annual installments after the grant date.
Are Chi Hanfeng’s iHuman (IH) option holdings direct or indirect?
The filing classifies all reported option positions as directly held. The ownership code is shown as “D,” and no footnotes indicate that the options are controlled through a separate trust, partnership, or other indirect ownership vehicle.